| Year |
Citation |
Score |
| 2024 |
Kumarasamy V, Wang J, Frangou C, Wan Y, Dynka A, Rosenheck H, Dey P, Abel EV, Knudsen ES, Witkiewicz AK. The extracellular niche and tumor microenvironment enhance KRAS inhibitor efficacy in pancreatic cancer. Cancer Research. PMID 38294344 DOI: 10.1158/0008-5472.CAN-23-2504 |
0.383 |
|
| 2023 |
Knudsen ES, Witkiewicz AK, Rubin SM. Cancer takes many paths through G1/S. Trends in Cell Biology. PMID 37953123 DOI: 10.1016/j.tcb.2023.10.007 |
0.321 |
|
| 2023 |
Kumarasamy V, Gao Z, Zhao B, Jiang B, Rubin SM, Burgess K, Witkiewicz AK, Knudsen ES. PROTAC-mediated CDK degradation differentially impacts cancer cell cycles due to heterogeneity in kinase dependencies. British Journal of Cancer. PMID 37626264 DOI: 10.1038/s41416-023-02399-4 |
0.386 |
|
| 2023 |
Kumarasamy V, Frangou C, Wang J, Wan Y, Dynka A, Rosenheck H, Dey P, Abel EV, Knudsen ES, Witkiewicz AK. Pharmacologically targeting KRAS in PDAC models: tumor cell intrinsic and extrinsic impact. Biorxiv : the Preprint Server For Biology. PMID 37162905 DOI: 10.1101/2023.03.18.533261 |
0.388 |
|
| 2022 |
Witkiewicz AK, Kumarasamy V, Sanidas I, Knudsen ES. Cancer cell cycle dystopia: heterogeneity, plasticity, and therapy. Trends in Cancer. PMID 35599231 DOI: 10.1016/j.trecan.2022.04.006 |
0.402 |
|
| 2022 |
Knudsen ES, Kumarasamy V, Nambiar R, Pearson JD, Vail P, Rosenheck H, Wang J, Eng K, Bremner R, Schramek D, Rubin SM, Welm AL, Witkiewicz AK. CDK/cyclin dependencies define extreme cancer cell-cycle heterogeneity and collateral vulnerabilities. Cell Reports. 38: 110448. PMID 35235778 DOI: 10.1016/j.celrep.2022.110448 |
0.458 |
|
| 2020 |
Kumarasamy V, Vail P, Nambiar R, Witkiewicz AK, Knudsen ES. Functional determinants of cell-cycle plasticity and sensitivity to CDK4/6 inhibition. Cancer Research. PMID 33323381 DOI: 10.1158/0008-5472.CAN-20-2275 |
0.412 |
|
| 2020 |
Braden WA, Lenihan JM, Lan Z, Luce KS, Zagorski W, Bosco E, Reed MF, Cook JG, Knudsen ES. Retraction for Braden et al., "Distinct Action of the Retinoblastoma Pathway on the DNA Replication Machinery Defines Specific Roles for Cyclin-Dependent Kinase Complexes in Prereplication Complex Assembly and S-Phase Progression". Molecular and Cellular Biology. 40. PMID 32817173 DOI: 10.1128/Mcb.00319-20 |
0.368 |
|
| 2020 |
Roberts PJ, Kumarasamy V, Witkiewicz AK, Knudsen ES. Chemotherapy and CDK4/6 inhibitors: Unexpected bedfellows. Molecular Cancer Therapeutics. PMID 32546660 DOI: 10.1158/1535-7163.Mct-18-1161 |
0.339 |
|
| 2020 |
Knudsen ES, Nambiar R, Rosario SR, Smiraglia DJ, Goodrich DW, Witkiewicz AK. Pan-cancer molecular analysis of the RB tumor suppressor pathway. Communications Biology. 3: 158. PMID 32242058 DOI: 10.1038/s42003-020-0873-9 |
0.348 |
|
| 2019 |
Guiley KZ, Stevenson JW, Lou K, Barkovich KJ, Kumarasamy V, Wijeratne TU, Bunch KL, Tripathi S, Knudsen ES, Witkiewicz AK, Shokat KM, Rubin SM. p27 allosterically activates cyclin-dependent kinase 4 and antagonizes palbociclib inhibition. Science (New York, N.Y.). 366. PMID 31831640 DOI: 10.1126/Science.Aaw2106 |
0.347 |
|
| 2019 |
Kumarasamy V, Ruiz A, Nambiar R, Witkiewicz AK, Knudsen ES. Chemotherapy impacts on the cellular response to CDK4/6 inhibition: distinct mechanisms of interaction and efficacy in models of pancreatic cancer. Oncogene. PMID 31745297 DOI: 10.1038/s41388-019-1102-1 |
0.347 |
|
| 2019 |
Knudsen ES, Pruitt SC, Hershberger PA, Witkiewicz AK, Goodrich DW. Cell Cycle and Beyond: Exploiting New RB1 Controlled Mechanisms for Cancer Therapy. Trends in Cancer. 5: 308-324. PMID 31174843 DOI: 10.1016/j.trecan.2019.03.005 |
0.333 |
|
| 2019 |
Knudsen ES, Kumarasamy V, Ruiz A, Sivinski J, Chung S, Grant A, Vail P, Chauhan SS, Jie T, Riall TS, Witkiewicz AK. Cell cycle plasticity driven by MTOR signaling: integral resistance to CDK4/6 inhibition in patient-derived models of pancreatic cancer. Oncogene. PMID 30696953 DOI: 10.1038/s41388-018-0650-0 |
0.343 |
|
| 2018 |
Chung S, Vail PJ, Witkiewicz AK, Knudsen ES. Coordinately targeting cell cycle checkpoint functions in integrated models of pancreatic cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30538111 DOI: 10.1158/1078-0432.CCR-18-1620 |
0.367 |
|
| 2018 |
Witkiewicz AK, Chung S, Brough R, Vail P, Franco J, Lord CJ, Knudsen ES. Targeting the Vulnerability of RB Tumor Suppressor Loss in Triple-Negative Breast Cancer. Cell Reports. 22: 1185-1199. PMID 29386107 DOI: 10.1016/j.celrep.2018.01.022 |
0.34 |
|
| 2017 |
Knudsen ES, Hutcheson J, Vail P, Witkiewicz AK. Biological specificity of CDK4/6 inhibitors: dose response relationship, in vivo signaling, and composite response signature. Oncotarget. PMID 28620137 DOI: 10.18632/Oncotarget.18435 |
0.38 |
|
| 2017 |
Jansen VM, Bhola NE, Bauer JA, Formisano L, Lee KM, Hutchinson KE, Witkiewicz AK, Moore PD, Estrada MV, Sanchez V, Ericsson PG, Sanders M, Pohlmann PR, Pishvaian MJ, Riddle DA, ... ... Knudsen E, et al. Kinome-wide RNA interference screen reveals a role for PDK1 in acquired resistance to CDK4/6 inhibition in ER-positive breast cancer. Cancer Research. PMID 28249908 DOI: 10.1158/0008-5472.Can-16-2653 |
0.355 |
|
| 2016 |
Knudsen ES, Balaji U, Freinkman E, McCue P, Witkiewicz AK. Unique metabolic features of pancreatic cancer stroma: relevance to the tumor compartment, prognosis, and invasive potential. Oncotarget. PMID 27623078 DOI: 10.18632/Oncotarget.11893 |
0.33 |
|
| 2016 |
Franco J, Balaji U, Freinkman E, Witkiewicz AK, Knudsen ES. Metabolic Reprogramming of Pancreatic Cancer Mediated by CDK4/6 Inhibition Elicits Unique Vulnerabilities. Cell Reports. PMID 26804906 DOI: 10.1016/J.Celrep.2015.12.094 |
0.327 |
|
| 2015 |
Witkiewicz AK, Borja NA, Franco J, Brody JR, Yeo CJ, Mansour J, Choti MA, McCue P, Knudsen ES. Selective impact of CDK4/6 suppression on patient-derived models of pancreatic cancer. Oncotarget. 6: 15788-801. PMID 26158861 DOI: 10.18632/Oncotarget.3819 |
0.343 |
|
| 2015 |
Hutcheson J, Witkiewicz AK, Knudsen ES. The RB tumor suppressor at the intersection of proliferation and immunity: relevance to disease immune evasion and immunotherapy. Cell Cycle (Georgetown, Tex.). 14: 3812-9. PMID 25714546 DOI: 10.1080/15384101.2015.1010922 |
0.323 |
|
| 2015 |
Asghar U, Witkiewicz AK, Turner NC, Knudsen ES. The history and future of targeting cyclin-dependent kinases in cancer therapy. Nature Reviews. Drug Discovery. 14: 130-46. PMID 25633797 DOI: 10.1038/nrd4504 |
0.329 |
|
| 2015 |
Knudsen ES, McClendon AK, Franco J, Ertel A, Fortina P, Witkiewicz AK. RB loss contributes to aggressive tumor phenotypes in MYC-driven triple negative breast cancer. Cell Cycle (Georgetown, Tex.). 14: 109-22. PMID 25602521 DOI: 10.4161/15384101.2014.967118 |
0.38 |
|
| 2014 |
Franco J, Witkiewicz AK, Knudsen ES. CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer. Oncotarget. 5: 6512-25. PMID 25156567 DOI: 10.18632/oncotarget.2270 |
0.319 |
|
| 2013 |
Thangavel C, Boopathi E, Ertel A, Lim M, Addya S, Fortina P, Witkiewicz AK, Knudsen ES. Regulation of miR106b cluster through the RB pathway: mechanism and functional targets. Cell Cycle (Georgetown, Tex.). 12: 98-111. PMID 23255112 DOI: 10.4161/cc.23029 |
0.383 |
|
| 2012 |
McClendon AK, Dean JL, Rivadeneira DB, Yu JE, Reed CA, Gao E, Farber JL, Force T, Koch WJ, Knudsen ES. CDK4/6 inhibition antagonizes the cytotoxic response to anthracycline therapy. Cell Cycle (Georgetown, Tex.). 11: 2747-55. PMID 22751436 DOI: 10.4161/Cc.21127 |
0.386 |
|
| 2012 |
Dean JL, McClendon AK, Knudsen ES. Modification of the DNA damage response by therapeutic CDK4/6 inhibition. The Journal of Biological Chemistry. 287: 29075-87. PMID 22733811 DOI: 10.1074/jbc.M112.365494 |
0.367 |
|
| 2012 |
Casimiro MC, Crosariol M, Loro E, Ertel A, Yu Z, Dampier W, Saria EA, Papanikolaou A, Stanek TJ, Li Z, Wang C, Fortina P, Addya S, Tozeren A, Knudsen ES, et al. ChIP sequencing of cyclin D1 reveals a transcriptional role in chromosomal instability in mice. The Journal of Clinical Investigation. 122: 833-43. PMID 22307325 DOI: 10.1172/Jci60256 |
0.311 |
|
| 2011 |
DelBove J, Rosson G, Strobeck M, Chen J, Archer TK, Wang W, Knudsen ES, Weissman BE. Identification of a core member of the SWI/SNF complex, BAF155/SMARCC1, as a human tumor suppressor gene. Epigenetics. 6: 1444-53. PMID 22139574 DOI: 10.4161/Epi.6.12.18492 |
0.815 |
|
| 2011 |
Bourgo RJ, Thangavel C, Ertel A, Bergseid J, McClendon AK, Wilkens L, Witkiewicz AK, Wang JY, Knudsen ES. RB restricts DNA damage-initiated tumorigenesis through an LXCXE-dependent mechanism of transcriptional control. Molecular Cell. 43: 663-72. PMID 21855804 DOI: 10.1016/J.Molcel.2011.06.029 |
0.4 |
|
| 2011 |
Bourgo RJ, Ehmer U, Sage J, Knudsen ES. RB deletion disrupts coordination between DNA replication licensing and mitotic entry in vivo. Molecular Biology of the Cell. 22: 931-9. PMID 21289097 DOI: 10.1091/Mbc.E10-11-0895 |
0.364 |
|
| 2010 |
Sharma A, Yeow WS, Ertel A, Coleman I, Clegg N, Thangavel C, Morrissey C, Zhang X, Comstock CE, Witkiewicz AK, Gomella L, Knudsen ES, Nelson PS, Knudsen KE. The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression. The Journal of Clinical Investigation. 120: 4478-92. PMID 21099110 DOI: 10.1172/Jci44239 |
0.387 |
|
| 2010 |
Li Z, Jiao X, Wang C, Shirley LA, Elsaleh H, Dahl O, Wang M, Soutoglou E, Knudsen ES, Pestell RG. Alternative cyclin D1 splice forms differentially regulate the DNA damage response. Cancer Research. 70: 8802-11. PMID 20940395 DOI: 10.1158/0008-5472.CAN-10-0312 |
0.36 |
|
| 2010 |
Kuwahara Y, Charboneau A, Knudsen ES, Weissman BE. Reexpression of hSNF5 in malignant rhabdoid tumor cell lines causes cell cycle arrest through a p21(CIP1/WAF1)-dependent mechanism. Cancer Research. 70: 1854-65. PMID 20179200 DOI: 10.1158/0008-5472.Can-09-1922 |
0.373 |
|
| 2010 |
Knudsen ES, Wang JY. Targeting the RB-pathway in cancer therapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 1094-9. PMID 20145169 DOI: 10.1158/1078-0432.CCR-09-0787 |
0.365 |
|
| 2010 |
Burkhart DL, Ngai LK, Roake CM, Viatour P, Thangavel C, Ho VM, Knudsen ES, Sage J. Regulation of RB transcription in vivo by RB family members. Molecular and Cellular Biology. 30: 1729-45. PMID 20100864 DOI: 10.1128/Mcb.00952-09 |
0.472 |
|
| 2010 |
Rivadeneira DB, Mayhew CN, Thangavel C, Sotillo E, Reed CA, Graña X, Knudsen ES. Proliferative suppression by CDK4/6 inhibition: complex function of the retinoblastoma pathway in liver tissue and hepatoma cells. Gastroenterology. 138: 1920-30. PMID 20100483 DOI: 10.1053/J.Gastro.2010.01.007 |
0.302 |
|
| 2010 |
McClendon AK, Dean JL, Ertel A, Knudsen ES. Differential impact of tumor suppressor pathways on DNA damage response and therapy-induced transformation in a mouse primary cell model. Plos One. 5: e8558. PMID 20049321 DOI: 10.1371/journal.pone.0008558 |
0.376 |
|
| 2010 |
Fan Y, Boivin GP, Knudsen ES, Nebert DW, Xia Y, Puga A. The aryl hydrocarbon receptor functions as a tumor suppressor of liver carcinogenesis. Cancer Research. 70: 212-20. PMID 19996281 DOI: 10.1158/0008-5472.Can-09-3090 |
0.378 |
|
| 2010 |
Reed CA, Mayhew CN, McClendon AK, Knudsen ES. Unique impact of RB loss on hepatic proliferation: tumorigenic stresses uncover distinct pathways of cell cycle control. The Journal of Biological Chemistry. 285: 1089-96. PMID 19887370 DOI: 10.1074/jbc.M109.043380 |
0.396 |
|
| 2010 |
Dean JL, McClendon AK, Stengel KR, Knudsen ES. Modeling the effect of the RB tumor suppressor on disease progression: dependence on oncogene network and cellular context. Oncogene. 29: 68-80. PMID 19802012 DOI: 10.1038/onc.2009.313 |
0.407 |
|
| 2009 |
Bourgo RJ, Siddiqui H, Fox S, Solomon D, Sansam CG, Yaniv M, Muchardt C, Metzger D, Chambon P, Roberts CW, Knudsen ES. SWI/SNF deficiency results in aberrant chromatin organization, mitotic failure, and diminished proliferative capacity. Molecular Biology of the Cell. 20: 3192-9. PMID 19458193 DOI: 10.1091/Mbc.E08-12-1224 |
0.765 |
|
| 2009 |
Stengel KR, Thangavel C, Solomon DA, Angus SP, Zheng Y, Knudsen ES. Retinoblastoma/p107/p130 pocket proteins: protein dynamics and interactions with target gene promoters. The Journal of Biological Chemistry. 284: 19265-71. PMID 19279001 DOI: 10.1074/jbc.M808740200 |
0.686 |
|
| 2009 |
Sotgia F, Casimiro MC, Bonuccelli G, Liu M, Whitaker-Menezes D, Er O, Daumer KM, Mercier I, Witkiewicz AK, Minetti C, Capozza F, Gormley M, Quong AA, Rui H, Frank PG, ... Knudsen ES, et al. Loss of caveolin-3 induces a lactogenic microenvironment that is protective against mammary tumor formation. The American Journal of Pathology. 174: 613-29. PMID 19164602 DOI: 10.2353/Ajpath.2009.080653 |
0.347 |
|
| 2009 |
Bourgo RJ, Braden WA, Wells SI, Knudsen ES. Activation of the retinoblastoma tumor suppressor mediates cell cycle inhibition and cell death in specific cervical cancer cell lines. Molecular Carcinogenesis. 48: 45-55. PMID 18506774 DOI: 10.1002/mc.20456 |
0.392 |
|
| 2008 |
Braden WA, McClendon AK, Knudsen ES. Cyclin-dependent kinase 4/6 activity is a critical determinant of pre-replication complex assembly. Oncogene. 27: 7083-93. PMID 18776921 DOI: 10.1038/onc.2008.319 |
0.458 |
|
| 2008 |
Popowski M, Ferguson HA, Sion AM, Koller E, Knudsen E, Berg CLVD. Stress and IGF-I differentially control cell fate through mammalian target of rapamycin (mTOR) and retinoblastoma protein (pRB). Journal of Biological Chemistry. 283: 28265-28273. PMID 18697743 DOI: 10.1074/Jbc.M805724200 |
0.456 |
|
| 2008 |
Wang Y, Dean JL, Millar EK, Tran TH, McNeil CM, Burd CJ, Henshall SM, Utama FE, Witkiewicz A, Rui H, Sutherland RL, Knudsen KE, Knudsen ES. Cyclin D1b is aberrantly regulated in response to therapeutic challenge and promotes resistance to estrogen antagonists. Cancer Research. 68: 5628-38. PMID 18632615 DOI: 10.1158/0008-5472.Can-07-3170 |
0.383 |
|
| 2008 |
Marlowe JL, Fan Y, Chang X, Peng L, Knudsen ES, Xia Y, Puga A. The aryl hydrocarbon receptor binds to E2F1 and inhibits E2F1-induced apoptosis. Molecular Biology of the Cell. 19: 3263-71. PMID 18524851 DOI: 10.1091/Mbc.E08-04-0359 |
0.533 |
|
| 2008 |
Hoskins EE, Gunawardena RW, Habash KB, Wise-Draper TM, Jansen M, Knudsen ES, Wells SI. Coordinate regulation of Fanconi anemia gene expression occurs through the Rb/E2F pathway Oncogene. 27: 4798-4808. PMID 18438432 DOI: 10.1038/onc.2008.121 |
0.433 |
|
| 2008 |
Peng L, Mayhew CN, Schnekenburger M, Knudsen ES, Puga A. Repression of Ah receptor and induction of transforming growth factor-beta genes in DEN-induced mouse liver tumors. Toxicology. 246: 242-7. PMID 18282651 DOI: 10.1016/J.Tox.2008.01.002 |
0.476 |
|
| 2008 |
Daria D, Filippi MD, Knudsen ES, Faccio R, Li Z, Kalfa T, Geiger H. The retinoblastoma tumor suppressor is a critical intrinsic regulator for hematopoietic stem and progenitor cells under stress. Blood. 111: 1894-902. PMID 18048646 DOI: 10.1182/Blood-2007-02-071746 |
0.431 |
|
| 2007 |
Mayhew CN, Carter SL, Fox SR, Sexton CR, Reed CA, Srinivasan SV, Liu X, Wikenheiser-Brokamp K, Boivin GP, Lee JS, Aronow BJ, Thorgeirsson SS, Knudsen ES. RB loss abrogates cell cycle control and genome integrity to promote liver tumorigenesis. Gastroenterology. 133: 976-84. PMID 17854601 DOI: 10.1053/J.Gastro.2007.06.025 |
0.357 |
|
| 2007 |
Zagorski WA, Knudsen ES, Reed MF. Retinoblastoma deficiency increases chemosensitivity in lung cancer. Cancer Research. 67: 8264-73. PMID 17804741 DOI: 10.1158/0008-5472.Can-06-4753 |
0.429 |
|
| 2007 |
Reed MF, Zagorski WA, Knudsen ES. RB activity alters checkpoint response and chemosensitivity in lung cancer lines. The Journal of Surgical Research. 142: 364-72. PMID 17640669 DOI: 10.1016/J.Jss.2007.03.038 |
0.411 |
|
| 2007 |
Sharma A, Comstock CE, Knudsen ES, Cao KH, Hess-Wilson JK, Morey LM, Barrera J, Knudsen KE. Retinoblastoma tumor suppressor status is a critical determinant of therapeutic response in prostate cancer cells. Cancer Research. 67: 6192-203. PMID 17616676 DOI: 10.1158/0008-5472.Can-06-4424 |
0.328 |
|
| 2007 |
Srinivasan SV, Mayhew CN, Schwemberger S, Zagorski W, Knudsen ES. RB loss promotes aberrant ploidy by deregulating levels and activity of DNA replication factors. The Journal of Biological Chemistry. 282: 23867-77. PMID 17556357 DOI: 10.1074/jbc.M700542200 |
0.459 |
|
| 2007 |
Gunawardena RW, Fox SR, Siddiqui H, Knudsen ES. SWI/SNF activity is required for the repression of deoxyribonucleotide triphosphate metabolic enzymes via the recruitment of mSin3B. The Journal of Biological Chemistry. 282: 20116-23. PMID 17510060 DOI: 10.1074/Jbc.M701406200 |
0.782 |
|
| 2007 |
Markey MP, Bergseid J, Bosco EE, Stengel K, Xu H, Mayhew CN, Schwemberger SJ, Braden WA, Jiang Y, Babcock GF, Jegga AG, Aronow BJ, Reed MF, Wang JY, Knudsen ES. Loss of the retinoblastoma tumor suppressor: differential action on transcriptional programs related to cell cycle control and immune function. Oncogene. 26: 6307-18. PMID 17452985 DOI: 10.1038/Sj.Onc.1210450 |
0.501 |
|
| 2007 |
Siddiqui H, Fox SR, Gunawardena RW, Knudsen ES. Loss of RB compromises specific heterochromatin modifications and modulates HP1alpha dynamics. Journal of Cellular Physiology. 211: 131-7. PMID 17245754 DOI: 10.1002/Jcp.20913 |
0.763 |
|
| 2007 |
Bosco EE, Wang Y, Xu H, Zilfou JT, Knudsen KE, Aronow BJ, Lowe SW, Knudsen ES. The retinoblastoma tumor suppressor modifies the therapeutic response of breast cancer. The Journal of Clinical Investigation. 117: 218-28. PMID 17160137 DOI: 10.1172/Jci28803 |
0.423 |
|
| 2007 |
Seeley SL, Bosco EE, Kramer E, Parysek LM, Knudsen ES. Distinct roles for RB loss on cell cycle control, cisplatin response, and immortalization in Schwann cells. Cancer Letters. 245: 205-17. PMID 16574317 DOI: 10.1016/J.Canlet.2006.01.028 |
0.525 |
|
| 2006 |
Knudsen ES, Sexton CR, Mayhew CN. Role of the retinoblastoma tumor suppressor in the maintenance of genome integrity. Current Molecular Medicine. 6: 749-57. PMID 17100601 DOI: 10.2174/1566524010606070749 |
0.49 |
|
| 2006 |
Braden WA, Lenihan JM, Lan Z, Luce KS, Zagorski W, Bosco E, Reed MF, Cook JG, Knudsen ES. Distinct action of the retinoblastoma pathway on the DNA replication machinery defines specific roles for cyclin-dependent kinase complexes in prereplication complex assembly and S-phase progression. Molecular and Cellular Biology. 26: 7667-81. PMID 16908528 DOI: 10.1128/Mcb.00045-06 |
0.508 |
|
| 2006 |
Knudsen ES, Knudsen KE. Retinoblastoma tumor suppressor: where cancer meets the cell cycle. Experimental Biology and Medicine (Maywood, N.J.). 231: 1271-81. PMID 16816134 DOI: 10.1177/153537020623100713 |
0.535 |
|
| 2006 |
Reed MF, Zagorski WA, Howington JA, Zilfou JT, Knudsen ES. Inhibition of retinoblastoma tumor suppressor activity by RNA interference in lung cancer lines. The Annals of Thoracic Surgery. 82: 249-53. PMID 16798224 DOI: 10.1016/J.Athoracsur.2006.02.033 |
0.362 |
|
| 2006 |
Knudsen KE, Diehl JA, Haiman CA, Knudsen ES. Cyclin D1: polymorphism, aberrant splicing and cancer risk. Oncogene. 25: 1620-8. PMID 16550162 DOI: 10.1038/Sj.Onc.1209371 |
0.385 |
|
| 2006 |
Burd CJ, Petre CE, Morey LM, Wang Y, Revelo MP, Haiman CA, Lu S, Fenoglio-Preiser CM, Li J, Knudsen ES, Wong J, Knudsen KE. Cyclin D1b variant influences prostate cancer growth through aberrant androgen receptor regulation Proceedings of the National Academy of Sciences of the United States of America. 103: 2190-2195. PMID 16461912 DOI: 10.1073/Pnas.0506281103 |
0.418 |
|
| 2006 |
Knauf JA, Ouyang B, Knudsen ES, Fukasawa K, Babcock G, Fagin JA. Oncogenic RAS induces accelerated transition through G2/M and promotes defects in the G2 DNA damage and mitotic spindle checkpoints. The Journal of Biological Chemistry. 281: 3800-9. PMID 16316983 DOI: 10.1074/Jbc.M511690200 |
0.341 |
|
| 2006 |
Reed M, Zagorski W, Dhamija A, Knudsen E. Inhibition of RB tumor suppressor activity increases chemosensitivity in lung cancer xenografts Journal of Surgical Research. 130: 291. DOI: 10.1016/J.Jss.2005.11.376 |
0.363 |
|
| 2005 |
Banine F, Bartlett C, Gunawardena R, Muchardt C, Yaniv M, Knudsen ES, Weissman BE, Sherman LS. SWI/SNF chromatin-remodeling factors induce changes in DNA methylation to promote transcriptional activation. Cancer Research. 65: 3542-7. PMID 15867346 DOI: 10.1158/0008-5472.Can-04-3554 |
0.521 |
|
| 2005 |
Bosco EE, Knudsen ES. Differential role of RB in response to UV and IR damage. Nucleic Acids Research. 33: 1581-92. PMID 15767283 DOI: 10.1093/Nar/Gki283 |
0.466 |
|
| 2005 |
An FQ, Compitello N, Horwitz E, Sramkoski M, Knudsen ES, Renne R. The latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus modulates cellular gene expression and protects lymphoid cells from p16 INK4A-induced cell cycle arrest. The Journal of Biological Chemistry. 280: 3862-74. PMID 15525642 DOI: 10.1074/jbc.M407435200 |
0.462 |
|
| 2004 |
Solomon DA, Cardoso MC, Knudsen ES. Dynamic targeting of the replication machinery to sites of DNA damage. The Journal of Cell Biology. 166: 455-63. PMID 15314062 DOI: 10.1083/Jcb.200312048 |
0.379 |
|
| 2004 |
Mayhew CN, Bosco EE, Solomon DA, Knudsen ES, Angus SP. Analysis of RB action in DNA damage checkpoint response. Methods in Molecular Biology (Clifton, N.J.). 281: 3-16. PMID 15220518 DOI: 10.1385/1-59259-811-0:003 |
0.729 |
|
| 2004 |
Angus SP, Mayhew CN, Solomon DA, Braden WA, Markey MP, Okuno Y, Cardoso MC, Gilbert DM, Knudsen ES. RB reversibly inhibits DNA replication via two temporally distinct mechanisms. Molecular and Cellular Biology. 24: 5404-20. PMID 15169903 DOI: 10.1128/Mcb.24.12.5404-5420.2004 |
0.75 |
|
| 2004 |
Powers JT, Hong S, Mayhew CN, Rogers PM, Knudsen ES, Johnson DG. E2F1 uses the ATM signaling pathway to induce p53 and Chk2 phosphorylation and apoptosis. Molecular Cancer Research : McR. 2: 203-14. PMID 15140942 |
0.382 |
|
| 2004 |
Marlowe JL, Knudsen ES, Schwemberger S, Puga A. The aryl hydrocarbon receptor displaces p300 from E2F-dependent promoters and represses S phase-specific gene expression. The Journal of Biological Chemistry. 279: 29013-22. PMID 15123621 DOI: 10.1074/Jbc.M404315200 |
0.469 |
|
| 2004 |
Gunawardena RW, Siddiqui H, Solomon DA, Mayhew CN, Held J, Angus SP, Knudsen ES. Hierarchical requirement of SWI/SNF in retinoblastoma tumor suppressor-mediated repression of Plk1. The Journal of Biological Chemistry. 279: 29278-85. PMID 15105433 DOI: 10.1074/Jbc.M400395200 |
0.823 |
|
| 2004 |
Markey M, Siddiqui H, Knudsen ES. Geminin is targeted for repression by the retinoblastoma tumor suppressor pathway through intragenic E2F sites. The Journal of Biological Chemistry. 279: 29255-62. PMID 15084580 DOI: 10.1074/Jbc.M313482200 |
0.798 |
|
| 2004 |
Mayhew CN, Perkin LM, Zhang X, Sage J, Jacks T, Knudsen ES. Discrete signaling pathways participate in RB-dependent responses to chemotherapeutic agents. Oncogene. 23: 4107-20. PMID 15064736 DOI: 10.1038/Sj.Onc.1207503 |
0.53 |
|
| 2004 |
Bosco EE, Mayhew CN, Hennigan RF, Sage J, Jacks T, Knudsen ES. RB signaling prevents replication-dependent DNA double-strand breaks following genotoxic insult Nucleic Acids Research. 32: 25-34. PMID 14704340 DOI: 10.1093/Nar/Gkg919 |
0.436 |
|
| 2004 |
Reed M, Zagorski W, Knudsen E. RB activity affects checkpoint control and chemosensitivity in lung cancer lines Journal of Surgical Research. 121: 281-282. DOI: 10.1016/J.Jss.2004.07.050 |
0.398 |
|
| 2003 |
Angus SP, Solomon DA, Kuschel L, Hennigan RF, Knudsen ES. Retinoblastoma Tumor Suppressor: Analyses of Dynamic Behavior in Living Cells Reveal Multiple Modes of Regulation Molecular and Cellular Biology. 23: 8172-8188. PMID 14585976 DOI: 10.1128/Mcb.23.22.8172-8188.2003 |
0.755 |
|
| 2003 |
Siddiqui H, Solomon DA, Gunawardena RW, Wang Y, Knudsen ES. Histone deacetylation of RB-responsive promoters: requisite for specific gene repression but dispensable for cell cycle inhibition. Molecular and Cellular Biology. 23: 7719-31. PMID 14560017 DOI: 10.1128/Mcb.23.21.7719-7731.2003 |
0.809 |
|
| 2003 |
Nath N, Wang S, Betts V, Knudsen E, Chellappan S. Apoptotic and mitogenic stimuli inactivate Rb by differential utilization of p38 and cyclin-dependent kinases. Oncogene. 22: 5986-94. PMID 12955077 DOI: 10.1038/Sj.Onc.1206843 |
0.432 |
|
| 2003 |
Gupta S, Luong MX, Bleuming SA, Miele A, Luong M, Young D, Knudsen ES, Van Wijnen AJ, Stein JL, Stein GS. Tumor suppressor pRB functions as a co-repressor of the CCAAT displacement protein (CDP/cut) to regulate cell cycle controlled histone H4 transcription. Journal of Cellular Physiology. 196: 541-56. PMID 12891711 DOI: 10.1002/Jcp.10335 |
0.532 |
|
| 2003 |
Solomon DA, Wang Y, Fox SR, Lambeck TC, Giesting S, Lan Z, Senderowicz AM, Conti CJ, Knudsen ES. Cyclin D1 splice variants. Differential effects on localization, RB phosphorylation, and cellular transformation. The Journal of Biological Chemistry. 278: 30339-47. PMID 12746453 DOI: 10.1074/Jbc.M303969200 |
0.468 |
|
| 2003 |
Knudsen ES, Angus SP. Functional analysis of the antimitogenic activity of tumor suppressors. Methods in Molecular Biology (Clifton, N.J.). 218: 3-15. PMID 12616708 DOI: 10.1385/1-59259-356-9:03 |
0.729 |
|
| 2002 |
Puga A, Marlowe J, Barnes S, Chang CY, Maier A, Tan Z, Kerzee JK, Chang X, Strobeck M, Knudsen ES. Role of the aryl hydrocarbon receptor in cell cycle regulation. Toxicology. 181: 171-7. PMID 12505305 DOI: 10.1016/S0300-483X(02)00276-7 |
0.502 |
|
| 2002 |
Markey MP, Angus SP, Strobeck MW, Williams SL, Gunawardena RW, Aronow BJ, Knudsen ES. Unbiased analysis of RB-mediated transcriptional repression identifies novel targets and distinctions from E2F action. Cancer Research. 62: 6587-97. PMID 12438254 |
0.817 |
|
| 2002 |
Angus SP, Wheeler LJ, Ranmal SA, Zhang X, Markey MP, Mathews CK, Knudsen ES. Retinoblastoma tumor suppressor targets dNTP metabolism to regulate DNA replication. The Journal of Biological Chemistry. 277: 44376-84. PMID 12221087 DOI: 10.1074/Jbc.M205911200 |
0.781 |
|
| 2002 |
Heinen CD, Goss KH, Cornelius JR, Babcock GF, Knudsen ES, Kowalik T, Groden J. The APC tumor suppressor controls entry into S-phase through its ability to regulate the cyclin D/RB pathway. Gastroenterology. 123: 751-63. PMID 12198702 DOI: 10.1053/Gast.2002.35382 |
0.383 |
|
| 2002 |
Betz BL, Strobeck MW, Reisman DN, Knudsen ES, Weissman BE. Re-expression of hSNF5/INI1/BAF47 in pediatric tumor cells leads to G1 arrest associated with induction of p16ink4a and activation of RB. Oncogene. 21: 5193-203. PMID 12149641 DOI: 10.1038/Sj.Onc.1205706 |
0.83 |
|
| 2002 |
Angus SP, Fribourg AF, Markey MP, Williams SL, Horn HF, DeGregori J, Kowalik TF, Fukasawa K, Knudsen ES. Active RB elicits late G1/S inhibition. Experimental Cell Research. 276: 201-13. PMID 12027450 DOI: 10.1006/Excr.2002.5510 |
0.759 |
|
| 2002 |
Reisman DN, Strobeck MW, Betz BL, Sciariotta J, Funkhouser W, Murchardt C, Yaniv M, Sherman LS, Knudsen ES, Weissman BE. Concomitant down-regulation of BRM and BRG1 in human tumor cell lines: differential effects on RB-mediated growth arrest vs CD44 expression. Oncogene. 21: 1196-207. PMID 11850839 DOI: 10.1038/sj.onc.1205188 |
0.821 |
|
| 2002 |
Lan Z, Sever-Chroneos Z, Strobeck MW, Park CH, Baskaran R, Edelmann W, Leone G, Knudsen ES. DNA damage invokes mismatch repair-dependent cyclin D1 attenuation and retinoblastoma signaling pathways to inhibit CDK2. The Journal of Biological Chemistry. 277: 8372-81. PMID 11726663 DOI: 10.1074/Jbc.M108906200 |
0.8 |
|
| 2002 |
Strobeck MW, Reisman DN, Gunawardena RW, Betz BL, Angus SP, Knudsen KE, Kowalik TF, Weissman BE, Knudsen ES. Compensation of BRG-1 function by Brm: insight into the role of the core SWI-SNF subunits in retinoblastoma tumor suppressor signaling. The Journal of Biological Chemistry. 277: 4782-9. PMID 11719516 DOI: 10.1074/Jbc.M109532200 |
0.81 |
|
| 2001 |
Sever-Chroneos Z, Angus SP, Fribourg AF, Wan H, Todorov I, Knudsen KE, Knudsen ES. Retinoblastoma tumor suppressor protein signals through inhibition of cyclin-dependent kinase 2 activity to disrupt PCNA function in S phase. Molecular and Cellular Biology. 21: 4032-45. PMID 11359910 DOI: 10.1128/Mcb.21.12.4032-4045.2001 |
0.757 |
|
| 2001 |
Strobeck MW, DeCristofaro MF, Banine F, Weissman BE, Sherman LS, Knudsen ES. The BRG-1 subunit of the SWI/SNF complex regulates CD44 expression. The Journal of Biological Chemistry. 276: 9273-8. PMID 11108719 DOI: 10.1074/Jbc.M009747200 |
0.777 |
|
| 2000 |
Okuda M, Horn HF, Tarapore P, Tokuyama Y, Smulian AG, Chan PK, Knudsen ES, Hofmann IA, Snyder JD, Bove KE, Fukasawa K. Nucleophosmin/B23 is a target of CDK2/cyclin E in centrosome duplication. Cell. 103: 127-40. PMID 11051553 DOI: 10.1016/S0092-8674(00)00093-3 |
0.369 |
|
| 2000 |
Knudsen KE, Booth D, Naderi S, Sever-Chroneos Z, Fribourg AF, Hunton IC, Feramisco JR, Wang JY, Knudsen ES. RB-dependent S-phase response to DNA damage. Molecular and Cellular Biology. 20: 7751-63. PMID 11003670 DOI: 10.1128/Mcb.20.20.7751-7763.2000 |
0.484 |
|
| 2000 |
Fribourg AF, Knudsen KE, Strobeck MW, Lindhorst CM, Knudsen ES. Differential requirements for ras and the retinoblastoma tumor suppressor protein in the androgen dependence of prostatic adenocarcinoma cells. Cell Growth & Differentiation : the Molecular Biology Journal of the American Association For Cancer Research. 11: 361-72. PMID 10939590 |
0.804 |
|
| 2000 |
Strobeck MW, Knudsen KE, Fribourg AF, DeCristofaro MF, Weissman BE, Imbalzano AN, Knudsen ES. BRG-1 is required for RB-mediated cell cycle arrest. Proceedings of the National Academy of Sciences of the United States of America. 97: 7748-53. PMID 10884406 DOI: 10.1073/Pnas.97.14.7748 |
0.832 |
|
| 2000 |
Strobeck MW, Fribourg AF, Puga A, Knudsen ES. Restoration of retinoblastoma mediated signaling to Cdk2 results in cell cycle arrest Oncogene. 19: 1857-1867. PMID 10773875 DOI: 10.1038/Sj.Onc.1203510 |
0.829 |
|
| 2000 |
Puga A, Barnes SJ, Dalton TP, Chang Cy, Knudsen ES, Maier MA. Aromatic hydrocarbon receptor interaction with the retinoblastoma protein potentiates repression of E2F-dependent transcription and cell cycle arrest. The Journal of Biological Chemistry. 275: 2943-50. PMID 10644764 DOI: 10.1074/Jbc.275.4.2943 |
0.556 |
|
| 1999 |
Knudsen KE, Weber E, Arden KC, Cavenee WK, Feramisco JR, Knudsen ES. The retinoblastoma tumor suppressor inhibits cellular proliferation through two distinct mechanisms: inhibition of cell cycle progression and induction of cell death. Oncogene. 18: 5239-45. PMID 10498874 DOI: 10.1038/Sj.Onc.1202910 |
0.576 |
|
| 1999 |
Knudsen KE, Fribourg AF, Strobeck MW, Blanchard JM, Knudsen ES. Cyclin A is a functional target of retinoblastoma tumor suppressor protein-mediated cell cycle arrest. The Journal of Biological Chemistry. 274: 27632-41. PMID 10488103 DOI: 10.1074/Jbc.274.39.27632 |
0.829 |
|
| 1999 |
Weber E, Ravi RK, Knudsen ES, Williams JR, Dillehay LE, Nelkin BD, Kalemkerian GP, Feramisco JR, Mabry M. Retinoic acid-mediated growth inhibition of small cell lung cancer cells is associated with reduced myc and increased p27Kip1 expression. International Journal of Cancer. Journal International Du Cancer. 80: 935-43. PMID 10074929 DOI: 10.1002/(Sici)1097-0215(19990315)80:6<935::Aid-Ijc21>3.0.Co;2-E |
0.354 |
|
| 1998 |
Knudsen ES, Buckmaster C, Chen TT, Feramisco JR, Wang JY. Inhibition of DNA synthesis by RB: effects on G1/S transition and S-phase progression. Genes & Development. 12: 2278-92. PMID 9694794 DOI: 10.1101/Gad.12.15.2278 |
0.514 |
|
| 1998 |
Whitaker LL, Su H, Baskaran R, Knudsen ES, Wang JY. Growth suppression by an E2F-binding-defective retinoblastoma protein (RB): contribution from the RB C pocket. Molecular and Cellular Biology. 18: 4032-42. PMID 9632788 DOI: 10.1128/Mcb.18.7.4032 |
0.394 |
|
| 1998 |
Knudsen ES, Wang JY. Hyperphosphorylated p107 and p130 bind to T-antigen: identification of a critical regulatory sequence present in RB but not in p107/p130. Oncogene. 16: 1655-63. PMID 9582013 DOI: 10.1038/Sj.Onc.1201682 |
0.316 |
|
| 1997 |
Arap W, Knudsen E, Sewell DA, Sidransky D, Wang JY, Huang HJ, Cavenee WK. Functional analysis of wild-type and malignant glioma derived CDKN2Abeta alleles: evidence for an RB-independent growth suppressive pathway. Oncogene. 15: 2013-20. PMID 9366518 DOI: 10.1038/Sj.Onc.1201389 |
0.44 |
|
| 1997 |
Knudsen ES, Wang JY. Dual mechanisms for the inhibition of E2F binding to RB by cyclin-dependent kinase-mediated RB phosphorylation. Molecular and Cellular Biology. 17: 5771-83. PMID 9315635 DOI: 10.1128/Mcb.17.10.5771 |
0.371 |
|
| 1997 |
Arap W, Knudsen ES, Wang JY, Cavenee WK, Huang HJ. Point mutations can inactivate in vitro and in vivo activities of p16(INK4a)/CDKN2A in human glioma. Oncogene. 14: 603-9. PMID 9053859 DOI: 10.1038/Sj.Onc.1200870 |
0.421 |
|
| 1997 |
Obeyesekere MN, Knudsen ES, Wang JYJ, Zimmerman SO. A mathematical model of the regulation of the G
1
phase of Rb +/+ and Rb —/— mouse embryonic fibroblasts and an osteosarcoma cell line Cell Proliferation. 30: 171-194. DOI: 10.1111/j.1365-2184.1997.tb00933.x |
0.306 |
|
| 1996 |
Knudsen KE, Knudsen ES, Wang JY, Subramani S. p34cdc2 kinase activity is maintained upon activation of the replication checkpoint in Schizosaccharomyces pombe. Proceedings of the National Academy of Sciences of the United States of America. 93: 8278-83. PMID 8710861 DOI: 10.1073/Pnas.93.16.8278 |
0.514 |
|
| 1996 |
Chen Y, Knudsen ES, Wang JY. Cells arrested in G1 by the v-Abl tyrosine kinase do not express cyclin A despite the hyperphosphorylation of RB. The Journal of Biological Chemistry. 271: 19637-40. PMID 8702661 DOI: 10.1074/Jbc.271.33.19637 |
0.469 |
|
| 1996 |
Knudsen ES, Wang JY. Differential regulation of retinoblastoma protein function by specific Cdk phosphorylation sites. The Journal of Biological Chemistry. 271: 8313-20. PMID 8626527 DOI: 10.1074/Jbc.271.14.8313 |
0.376 |
|
| Low-probability matches (unlikely to be authored by this person) |
| 2016 |
Knudsen ES, Witkiewicz AK. Defining the transcriptional and biological response to CDK4/6 inhibition in relation to ER+/HER2- breast cancer. Oncotarget. PMID 27564114 DOI: 10.18632/oncotarget.11588 |
0.3 |
|
| 2014 |
Hutcheson J, Bourgo RJ, Balaji U, Ertel A, Witkiewicz AK, Knudsen ES. Retinoblastoma protein potentiates the innate immune response in hepatocytes: significance for hepatocellular carcinoma. Hepatology (Baltimore, Md.). 60: 1231-40. PMID 24824777 DOI: 10.1002/Hep.27217 |
0.299 |
|
| 2011 |
McClendon AK, Dean JL, Ertel A, Fu Z, Rivadeneira DB, Reed CA, Bourgo RJ, Witkiewicz A, Addya S, Mayhew CN, Grimes HL, Fortina P, Knudsen ES. RB and p53 cooperate to prevent liver tumorigenesis in response to tissue damage. Gastroenterology. 141: 1439-50. PMID 21704587 DOI: 10.1053/J.Gastro.2011.06.046 |
0.299 |
|
| 2011 |
Comstock CE, Augello MA, Schiewer MJ, Karch J, Burd CJ, Ertel A, Knudsen ES, Jessen WJ, Aronow BJ, Knudsen KE. Cyclin D1 is a selective modifier of androgen-dependent signaling and androgen receptor function. The Journal of Biological Chemistry. 286: 8117-27. PMID 21212260 DOI: 10.1074/Jbc.M110.170720 |
0.297 |
|
| 2011 |
Witkiewicz AK, Knudsen KE, Dicker AP, Knudsen ES. The meaning of p16(ink4a) expression in tumors: functional significance, clinical associations and future developments. Cell Cycle (Georgetown, Tex.). 10: 2497-503. PMID 21775818 DOI: 10.4161/Cc.10.15.16776 |
0.292 |
|
| 2018 |
Vaseva AV, Blake DR, Gilbert TSK, Ng S, Hostetter G, Azam SH, Ozkan-Dagliyan I, Gautam P, Bryant KL, Pearce KH, Herring LE, Han H, Graves LM, Witkiewicz AK, Knudsen ES, et al. KRAS Suppression-Induced Degradation of MYC Is Antagonized by a MEK5-ERK5 Compensatory Mechanism. Cancer Cell. 34: 807-822.e7. PMID 30423298 DOI: 10.1016/J.Ccell.2018.10.001 |
0.292 |
|
| 2023 |
Finnegan RM, Elshazly AM, Patel NH, Tyutyunyk-Massey L, Tran TH, Kumarasamy V, Knudsen ES, Gewirtz DA. The BET inhibitor/degrader ARV-825 prolongs the growth arrest response to Fulvestrant + Palbociclib and suppresses proliferative recovery in ER-positive breast cancer. Frontiers in Oncology. 12: 966441. PMID 36741704 DOI: 10.3389/fonc.2022.966441 |
0.281 |
|
| 2008 |
Knudsen ES, Knudsen KE. Tailoring to RB: tumour suppressor status and therapeutic response. Nature Reviews. Cancer. 8: 714-24. PMID 19143056 DOI: 10.1038/Nrc2401 |
0.281 |
|
| 2009 |
Sotgia F, Del Galdo F, Casimiro MC, Bonuccelli G, Mercier I, Whitaker-Menezes D, Daumer KM, Zhou J, Wang C, Katiyar S, Xu H, Bosco E, Quong AA, Aronow B, Witkiewicz AK, ... Knudsen ES, et al. Caveolin-1-/- null mammary stromal fibroblasts share characteristics with human breast cancer-associated fibroblasts. The American Journal of Pathology. 174: 746-61. PMID 19234134 DOI: 10.2353/Ajpath.2009.080658 |
0.28 |
|
| 2018 |
Brough R, Gulati A, Haider S, Kumar R, Campbell J, Knudsen E, Pettitt SJ, Ryan CJ, Lord CJ. Identification of highly penetrant Rb-related synthetic lethal interactions in triple negative breast cancer. Oncogene. PMID 29915391 DOI: 10.1038/s41388-018-0368-z |
0.28 |
|
| 2014 |
Witkiewicz AK, Cox DW, Rivadeneira D, Ertel AE, Fortina P, Schwartz GF, Knudsen ES. The retinoblastoma tumor suppressor pathway modulates the invasiveness of ErbB2-positive breast cancer. Oncogene. 33: 3980-91. PMID 24121271 DOI: 10.1038/Onc.2013.367 |
0.277 |
|
| 2009 |
Reed CA, Mayhew CN, McClendon AK, Yang X, Witkiewicz A, Knudsen ES. RB has a critical role in mediating the in vivo checkpoint response, mitigating secondary DNA damage and suppressing liver tumorigenesis initiated by aflatoxin B1. Oncogene. 28: 4434-43. PMID 19838213 DOI: 10.1038/onc.2009.303 |
0.276 |
|
| 2011 |
Thangavel C, Dean JL, Ertel A, Knudsen KE, Aldaz CM, Witkiewicz AK, Clarke R, Knudsen ES. Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer. Endocrine-Related Cancer. 18: 333-45. PMID 21367843 DOI: 10.1530/Erc-10-0262 |
0.272 |
|
| 2022 |
Matsukawa T, Yin M, Baslan T, Chung YJ, Cao D, Bertoli R, Zhu YJ, Walker RL, Freeland A, Knudsen E, Lowe SW, Meltzer PS, Aplan PD. Mcm2 hypomorph leads to acute leukemia or hematopoietic stem cell failure, dependent on genetic context. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 36: e22430. PMID 35920299 DOI: 10.1096/fj.202200061RR |
0.27 |
|
| 2005 |
Mayhew CN, Bosco EE, Fox SR, Okaya T, Tarapore P, Schwemberger SJ, Babcock GF, Lentsch AB, Fukasawa K, Knudsen ES. Liver-specific pRB loss results in ectopic cell cycle entry and aberrant ploidy. Cancer Research. 65: 4568-77. PMID 15930274 DOI: 10.1158/0008-5472.Can-04-4221 |
0.268 |
|
| 2007 |
Zagorski W, Knudsen E, Reed M. 178 Journal of Surgical Research. 137: 227. DOI: 10.1016/J.Jss.2006.12.193 |
0.266 |
|
| 2022 |
Langille E, Al-Zahrani KN, Ma Z, Liang M, Uuskula-Reimand L, Espin R, Teng K, Malik A, Bergholtz H, El Ghamrasni S, Afiuni-Zadeh S, Tsai R, Alvi S, Elia A, Lu Y, ... ... Knudsen ES, et al. Loss of epigenetic regulation disrupts lineage integrity, induces aberrant alveogenesis and promotes breast cancer. Cancer Discovery. PMID 36108220 DOI: 10.1158/2159-8290.CD-21-0865 |
0.266 |
|
| 2014 |
Witkiewicz AK, Cox D, Knudsen ES. CDK4/6 inhibition provides a potent adjunct to Her2-targeted therapies in preclinical breast cancer models. Genes & Cancer. 5: 261-72. PMID 25221644 |
0.263 |
|
| 2015 |
Knudsen E, Franco J, Witkiewicz A. Targeting unique metabolic vulnerabilities in dormant ER+ tumor cells Annals of Oncology. 26: iii29. DOI: 10.1093/ANNONC/MDV120.03 |
0.262 |
|
| 2011 |
Martinez-Outschoorn UE, Prisco M, Ertel A, Tsirigos A, Lin Z, Pavlides S, Wang C, Flomenberg N, Knudsen ES, Howell A, Pestell RG, Sotgia F, Lisanti MP. Ketones and lactate increase cancer cell "stemness," driving recurrence, metastasis and poor clinical outcome in breast cancer: achieving personalized medicine via Metabolo-Genomics. Cell Cycle (Georgetown, Tex.). 10: 1271-86. PMID 21512313 DOI: 10.4161/Cc.10.8.15330 |
0.261 |
|
| 2006 |
Knudsen E. Editorial [Hot Topic: The RB-Pathway in Cancer (Executive Editor: Erik Knudsen)] Current Molecular Medicine. 6: 703-704. DOI: 10.2174/1566524010606070703 |
0.259 |
|
| 1994 |
Wang JY, Knudsen ES, Welch PJ. The retinoblastoma tumor suppressor protein. Advances in Cancer Research. 64: 25-85. PMID 7879661 DOI: 10.1016/S0065-230X(08)60834-9 |
0.258 |
|
| 2008 |
Mercier I, Casimiro MC, Wang C, Rosenberg AL, Quong J, Minkeu A, Allen KG, Danilo C, Sotgia F, Bonuccelli G, Jasmin JF, Xu H, Bosco E, Aronow B, Witkiewicz A, ... Knudsen ES, et al. Human breast cancer-associated fibroblasts (CAFs) show caveolin-1 downregulation and RB tumor suppressor functional inactivation: Implications for the response to hormonal therapy Cancer Biology and Therapy. 7: 1212-1225. PMID 18458534 DOI: 10.4161/Cbt.7.8.6220 |
0.251 |
|
| 2022 |
Kumarasamy V, Nambiar R, Wang J, Rosenheck H, Witkiewicz AK, Knudsen ES. RB loss determines selective resistance and novel vulnerabilities in ER-positive breast cancer models. Oncogene. PMID 35676324 DOI: 10.1038/s41388-022-02362-2 |
0.246 |
|
| 2022 |
Hamad SH, Montgomery SA, Simon JM, Bowman BM, Spainhower KB, Murphy RM, Knudsen ES, Fenton SE, Randell SH, Holt JR, Hayes DN, Witkiewicz AK, Oliver TG, Major MB, Weissman BE. TP53, CDKN2A/P16, and NFE2L2/NRF2 regulate the incidence of pure- and combined-small cell lung cancer in mice. Oncogene. PMID 35577980 DOI: 10.1038/s41388-022-02348-0 |
0.245 |
|
| 2017 |
Knudsen ES, Witkiewicz AK. The Strange Case of CDK4/6 Inhibitors: Mechanisms, Resistance, and Combination Strategies. Trends in Cancer. 3: 39-55. PMID 28303264 DOI: 10.1016/j.trecan.2016.11.006 |
0.244 |
|
| 2009 |
Rojas P, Benavides F, Blando J, Perez C, Cardenas K, Richie E, Knudsen ES, Johnson DG, Senderowicz AM, Rodriguez-Puebla ML, Conti CJ. Enhanced skin carcinogenesis and lack of thymus hyperplasia in transgenic mice expressing human cyclin D1b (CCND1b). Molecular Carcinogenesis. 48: 508-16. PMID 18942117 DOI: 10.1002/Mc.20489 |
0.238 |
|
| 2002 |
Biegel JA, Kalpana G, Knudsen ES, Packer RJ, Roberts CW, Thiele CJ, Weissman B, Smith M. The role of INI1 and the SWI/SNF complex in the development of rhabdoid tumors: meeting summary from the workshop on childhood atypical teratoid/rhabdoid tumors. Cancer Research. 62: 323-8. PMID 11782395 |
0.234 |
|
| 2015 |
Casimiro MC, Di Sante G, Crosariol M, Loro E, Dampier W, Ertel A, Yu Z, Saria EA, Papanikolaou A, Li Z, Wang C, Addya S, Lisanti MP, Fortina P, Cardiff RD, ... ... Knudsen ES, et al. Kinase-independent role of cyclin D1 in chromosomal instability and mammary tumorigenesis. Oncotarget. 6: 8525-38. PMID 25940700 DOI: 10.18632/Oncotarget.3267 |
0.233 |
|
| 2010 |
Dean JL, Thangavel C, McClendon AK, Reed CA, Knudsen ES. Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure. Oncogene. 29: 4018-32. PMID 20473330 DOI: 10.1038/onc.2010.154 |
0.232 |
|
| 2008 |
Stengel KR, Dean JL, Seeley SL, Mayhew CN, Knudsen ES. RB status governs differential sensitivity to cytotoxic and molecularly-targeted therapeutic agents. Cell Cycle (Georgetown, Tex.). 7: 1095-103. PMID 18414045 DOI: 10.4161/cc.7.8.5737 |
0.232 |
|
| 2019 |
Bryant KL, Stalnecker CA, Zeitouni D, Klomp JE, Peng S, Tikunov AP, Gunda V, Pierobon M, Waters AM, George SD, Tomar G, Papke B, Hobbs GA, Yan L, Hayes TK, ... ... Knudsen ES, et al. Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer. Nature Medicine. PMID 30833752 DOI: 10.1038/S41591-019-0368-8 |
0.232 |
|
| 2012 |
Dean JL, McClendon AK, Hickey TE, Butler LM, Tilley WD, Witkiewicz AK, Knudsen ES. Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors. Cell Cycle (Georgetown, Tex.). 11: 2756-61. PMID 22767154 DOI: 10.4161/cc.21195 |
0.231 |
|
| 2014 |
Baek G, Tse YF, Hu Z, Cox D, Buboltz N, McCue P, Yeo CJ, White MA, DeBerardinis RJ, Knudsen ES, Witkiewicz AK. MCT4 defines a glycolytic subtype of pancreatic cancer with poor prognosis and unique metabolic dependencies. Cell Reports. 9: 2233-49. PMID 25497091 DOI: 10.1016/j.celrep.2014.11.025 |
0.228 |
|
| 2010 |
Martinez-Outschoorn UE, Balliet RM, Rivadeneira DB, Chiavarina B, Pavlides S, Wang C, Whitaker-Menezes D, Daumer KM, Lin Z, Witkiewicz AK, Flomenberg N, Howell A, Pestell RG, Knudsen ES, Sotgia F, et al. Oxidative stress in cancer associated fibroblasts drives tumor-stroma co-evolution: A new paradigm for understanding tumor metabolism, the field effect and genomic instability in cancer cells. Cell Cycle (Georgetown, Tex.). 9: 3256-76. PMID 20814239 DOI: 10.4161/Cc.9.16.12553 |
0.228 |
|
| 2009 |
Comstock CE, Augello MA, Benito RP, Karch J, Tran TH, Utama FE, Tindall EA, Wang Y, Burd CJ, Groh EM, Hoang HN, Giles GG, Severi G, Hayes VM, Henderson BE, ... ... Knudsen ES, et al. Cyclin D1 splice variants: polymorphism, risk, and isoform-specific regulation in prostate cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 5338-49. PMID 19706803 DOI: 10.1158/1078-0432.Ccr-08-2865 |
0.223 |
|
| 2017 |
Knudsen ES, Witkiewicz AK. The transcriptome of CDK4/6 inhibition. Aging. PMID 28860413 DOI: 10.18632/aging.101285 |
0.221 |
|
| 2011 |
Witkiewicz AK, Rivadeneira DB, Ertel A, Kline J, Hyslop T, Schwartz GF, Fortina P, Knudsen ES. Association of RB/p16-pathway perturbations with DCIS recurrence: dependence on tumor versus tissue microenvironment. The American Journal of Pathology. 179: 1171-8. PMID 21756866 DOI: 10.1016/J.Ajpath.2011.05.043 |
0.219 |
|
| 2007 |
Bosco EE, Knudsen ES. RB in breast cancer: at the crossroads of tumorigenesis and treatment. Cell Cycle (Georgetown, Tex.). 6: 667-71. PMID 17361100 DOI: 10.4161/cc.6.6.3988 |
0.217 |
|
| 2018 |
Knudsen ES, Zacksenhaus E. The vulnerability of RB loss in breast cancer: Targeting a void in cell cycle control. Oncotarget. 9: 30940-30941. PMID 30123416 DOI: 10.18632/oncotarget.25797 |
0.209 |
|
| 2014 |
Reed C, Hutcheson J, Mayhew CN, Witkiewicz AK, Knudsen ES. RB tumor suppressive function in response to xenobiotic hepatocarcinogens. The American Journal of Pathology. 184: 1853-9. PMID 24726645 DOI: 10.1016/J.Ajpath.2014.02.025 |
0.209 |
|
| 2014 |
Witkiewicz AK, Knudsen ES. Retinoblastoma tumor suppressor pathway in breast cancer: prognosis, precision medicine, and therapeutic interventions. Breast Cancer Research : Bcr. 16: 207. PMID 25223380 DOI: 10.1186/bcr3652 |
0.201 |
|
| 2020 |
Gandhi S, Pandey MR, Attwood K, Ji W, Witkiewicz AK, Knudsen ES, Allen C, Tario JD, Wallace PK, Cedeno CD, Levis M, Stack S, Funchain P, Drabick JJ, Bucsek MJ, et al. Phase I clinical trial of combination propranolol and pembrolizumab in locally advanced and metastatic melanoma: Safety, Tolerability, and Preliminary Evidence of Antitumor Activity. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 33127652 DOI: 10.1158/1078-0432.CCR-20-2381 |
0.2 |
|
| 2023 |
Witkiewicz AK, Schultz E, Wang J, Hamilton D, Levine E, O'Connor T, Knudsen ES. Determinants of response to CDK4/6 inhibitors in the real-world setting. Npj Precision Oncology. 7: 90. PMID 37704753 DOI: 10.1038/s41698-023-00438-0 |
0.2 |
|
| 2009 |
Millar EK, Dean JL, McNeil CM, O'Toole SA, Henshall SM, Tran T, Lin J, Quong A, Comstock CE, Witkiewicz A, Musgrove EA, Rui H, Lemarchand L, Setiawan VW, Haiman CA, ... Knudsen ES, et al. Cyclin D1b protein expression in breast cancer is independent of cyclin D1a and associated with poor disease outcome. Oncogene. 28: 1812-20. PMID 19287456 DOI: 10.1038/Onc.2009.13 |
0.196 |
|
| 2017 |
Adams TA, Vail PJ, Ruiz A, Mollaee M, McCue PA, Knudsen ES, Witkiewicz AK. Composite analysis of immunological and metabolic markers defines novel subtypes of triple negative breast cancer. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. PMID 28984302 DOI: 10.1038/modpathol.2017.126 |
0.193 |
|
| 2009 |
Knudsen ES. Replication factors controlling G1: A checkpoint for pre-replication complex assembly Cell Cycle. 8: 3-5. DOI: 10.4161/cc.8.1.7672 |
0.191 |
|
| 2022 |
Hamad SH, Montgomery SA, Simon JM, Bowman BM, Spainhower KB, Murphy RM, Knudsen ES, Fenton SE, Randell SH, Holt JR, Hayes DN, Witkiewicz AK, Oliver TG, Major MB, Weissman BE. Correction: TP53, CDKN2A/P16, and NFE2L2/NRF2 regulate the incidence of pure- and combined-small cell lung cancer in mice. Oncogene. PMID 36002660 DOI: 10.1038/s41388-022-02442-3 |
0.189 |
|
| 2015 |
Witkiewicz AK, McMillan EA, Balaji U, Baek G, Lin WC, Mansour J, Mollaee M, Wagner KU, Koduru P, Yopp A, Choti MA, Yeo CJ, McCue P, White MA, Knudsen ES. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nature Communications. 6: 6744. PMID 25855536 DOI: 10.1038/ncomms7744 |
0.189 |
|
| 2016 |
Witkiewicz AK, Balaji U, Eslinger C, McMillan E, Conway W, Posner B, Mills GB, O'Reilly EM, Knudsen ES. Integrated Patient-Derived Models Delineate Individualized Therapeutic Vulnerabilities of Pancreatic Cancer. Cell Reports. PMID 27498862 DOI: 10.1016/j.celrep.2016.07.023 |
0.188 |
|
| 2012 |
Knudsen ES, Ertel A, Davicioni E, Kline J, Schwartz GF, Witkiewicz AK. Progression of ductal carcinoma in situ to invasive breast cancer is associated with gene expression programs of EMT and myoepithelia. Breast Cancer Research and Treatment. 133: 1009-24. PMID 22134623 DOI: 10.1007/s10549-011-1894-3 |
0.185 |
|
| 2020 |
Weinberg BA, Wang H, Witkiewicz AK, Marshall JL, He AR, Vail P, Knudsen ES, Pishvaian MJ. A Phase I Study of Ribociclib Plus Everolimus in Patients with Metastatic Pancreatic Adenocarcinoma Refractory to Chemotherapy. Journal of Pancreatic Cancer. 6: 45-54. PMID 32642630 DOI: 10.1089/pancan.2020.0005 |
0.183 |
|
| 2019 |
Grant AD, Vail P, Padi M, Witkiewicz AK, Knudsen ES. Interrogating Mutant Allele Expression via Customized Reference Genomes to Define Influential Cancer Mutations. Scientific Reports. 9: 12766. PMID 31484939 DOI: 10.1038/s41598-019-48967-8 |
0.182 |
|
| 2010 |
Ertel A, Dean JL, Rui H, Liu C, Witkiewicz AK, Knudsen KE, Knudsen ES. RB-pathway disruption in breast cancer: differential association with disease subtypes, disease-specific prognosis and therapeutic response. Cell Cycle (Georgetown, Tex.). 9: 4153-63. PMID 20948315 DOI: 10.4161/Cc.9.20.13454 |
0.177 |
|
| 2021 |
Pearson JD, Huang K, Pacal M, McCurdy SR, Lu S, Aubry A, Yu T, Wadosky KM, Zhang L, Wang T, Gregorieff A, Ahmad M, Dimaras H, Langille E, Cole SPC, ... Knudsen ES, et al. Binary pan-cancer classes with distinct vulnerabilities defined by pro- or anti-cancer YAP/TEAD activity. Cancer Cell. PMID 34270926 DOI: 10.1016/j.ccell.2021.06.016 |
0.17 |
|
| 2013 |
Knudsen ES, Dervishaj O, Kleer CG, Pajak T, Schwartz GF, Witkiewicz AK. EZH2 and ALDH1 expression in ductal carcinoma in situ: complex association with recurrence and progression to invasive breast cancer. Cell Cycle (Georgetown, Tex.). 12: 2042-50. PMID 23759596 DOI: 10.4161/cc.25065 |
0.165 |
|
| 2016 |
Hutcheson J, Balaji U, Porembka MR, Wachsmann MB, McCue PA, Knudsen ES, Witkiewicz AK. Immunologic and Metabolic Features of Pancreatic Ductal Adenocarcinoma Define Prognostic Subtypes of Disease. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26858311 DOI: 10.1158/1078-0432.Ccr-15-1883 |
0.16 |
|
| 2020 |
Knudsen ES, Shapiro GI, Keyomarsi K. Selective CDK4/6 Inhibitors: Biologic Outcomes, Determinants of Sensitivity, Mechanisms of Resistance, Combinatorial Approaches, and Pharmacodynamic Biomarkers. American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting. 40: 115-126. PMID 32421454 DOI: 10.1200/EDBK_281085 |
0.157 |
|
| 2020 |
Franco J, Balaji U, Freinkman E, Witkiewicz AK, Knudsen ES. Metabolic Reprogramming of Pancreatic Cancer Mediated by CDK4/6 Inhibition Elicits Unique Vulnerabilities. Cell Reports. 32: 107793. PMID 32640213 DOI: 10.1016/j.celrep.2020.107793 |
0.149 |
|
| 2012 |
Witkiewicz AK, Ertel A, McFalls J, Valsecchi ME, Schwartz G, Knudsen ES. RB-pathway disruption is associated with improved response to neoadjuvant chemotherapy in breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 5110-22. PMID 22811582 DOI: 10.1158/1078-0432.CCR-12-0903 |
0.14 |
|
| 2018 |
Mannakee BK, Balaji U, Witkiewicz AK, Gutenkunst RN, Knudsen ES. Sensitive and specific post-call filtering of genetic variants in xenograft and primary tumors. Bioinformatics (Oxford, England). PMID 29325072 DOI: 10.1093/Bioinformatics/Bty010 |
0.124 |
|
| 2012 |
Knudsen ES, Pajak TF, Qeenan M, McClendon AK, Armon BD, Schwartz GF, Witkiewicz AK. Retinoblastoma and phosphate and tensin homolog tumor suppressors: impact on ductal carcinoma in situ progression. Journal of the National Cancer Institute. 104: 1825-36. PMID 23197489 DOI: 10.1093/jnci/djs446 |
0.123 |
|
| 2020 |
Knudsen ES, Kumarasamy V, Chung S, Ruiz A, Vail P, Tzetzo S, Wu J, Nambiar R, Seshadri M, Abrams SI, Wang J, Witkiewicz AK. Targeting dual signalling pathways in concert with immune checkpoints for the treatment of pancreatic cancer. Gut. PMID 32424005 DOI: 10.1136/Gutjnl-2020-321000 |
0.122 |
|
| 2013 |
Littman SJ, Knudsen ES, Witkiewicz A, Hyslop T, Lewis N, Pillai MV, Brus C, Mitchell EP. A phase II study of PD-0332991 in patients with advanced hepatocellular cancer. Journal of Clinical Oncology. 31: 321-321. DOI: 10.1200/Jco.2013.31.4_Suppl.321 |
0.122 |
|
| 2018 |
Weinberg BA, Wang H, Witkiewicz AK, Marshall J, Knudsen ES, Pishvaian MJ. A phase I/II study of ribociclib plus everolimus in patients (pts) with metastatic pancreatic adenocarcinoma (mPAC) refractory to chemotherapy. Journal of Clinical Oncology. 36: TPS4150-TPS4150. DOI: 10.1200/Jco.2018.36.15_Suppl.Tps4150 |
0.122 |
|
| 2019 |
Jansen VM, Bhola NE, Bauer JA, Formisano L, Lee KM, Hutchinson KE, Witkiewicz AK, Moore PD, Estrada MV, Sánchez V, Ericsson PG, Sanders ME, Pohlmann PR, Pishvaian MJ, Riddle DA, ... Knudsen ES, et al. Correction: Kinome-Wide RNA Interference Screen Reveals a Role for PDK1 in Acquired Resistance to CDK4/6 Inhibition in ER-Positive Breast Cancer. Cancer Research. 79: 874. PMID 30770369 DOI: 10.1158/0008-5472.Can-18-4086 |
0.114 |
|
| 2020 |
Bryant KL, Stalnecker CA, Zeitouni D, Klomp JE, Peng S, Tikunov AP, Gunda V, Pierobon M, Waters AM, George SD, Tomar G, Papke B, Hobbs GA, Yan L, Hayes TK, ... ... Knudsen ES, et al. Author Correction: Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer. Nature Medicine. PMID 32483362 DOI: 10.1038/S41591-020-0947-8 |
0.106 |
|
| 2017 |
Knudsen ES, Balaji U, Mannakee B, Vail P, Eslinger C, Moxom C, Mansour J, Witkiewicz AK. Pancreatic cancer cell lines as patient-derived avatars: genetic characterisation and functional utility. Gut. PMID 28073890 DOI: 10.1136/gutjnl-2016-313133 |
0.104 |
|
| 2021 |
Witkiewicz AK, Cox D, Knudsen ES. Correction: CDK4/6 inhibition provides a potent adjunct to Her2-targeted therapies in preclinical breast cancer models. Genes & Cancer. 12: 25-27. PMID 33884103 DOI: 10.18632/genesandcancer.211 |
0.099 |
|
| 2014 |
Knudsen ES, Gopal P, Singal AG. The changing landscape of hepatocellular carcinoma: etiology, genetics, and therapy. The American Journal of Pathology. 184: 574-83. PMID 24388934 DOI: 10.1016/j.ajpath.2013.10.028 |
0.098 |
|
| 2012 |
Myklebust MP, Li Z, Tran TH, Rui H, Knudsen ES, Elsaleh H, Fluge Ø, Vonen B, Myrvold HE, Leh S, Tveit KM, Pestell RG, Dahl O. Expression of cyclin D1a and D1b as predictive factors for treatment response in colorectal cancer. British Journal of Cancer. 107: 1684-91. PMID 23099809 DOI: 10.1038/Bjc.2012.463 |
0.097 |
|
| 2016 |
Knudsen ES, O'Reilly EM, Brody JR, Witkiewicz AK. Genetic Diversity of Pancreatic Ductal Adenocarcinoma and Opportunities for Precision Medicine. Gastroenterology. 150: 48-63. PMID 26385075 DOI: 10.1053/J.Gastro.2015.08.056 |
0.097 |
|
| 2014 |
Knudsen E, Cox D, Franco J, Frankel A, Haley B, Witkiewicz A. Targeting CDK4/6 in Her2 Positive Breast Cancer: Therapeutic Effect, Markers, and Combination Strategies Annals of Oncology. 25: i21. DOI: 10.1093/ANNONC/MDU069.1 |
0.09 |
|
| 2022 |
Knudsen ES, Schultz E, Hamilton D, Attwood K, Edge S, O'Connor T, Levine E, Witkiewicz AK. Real-World Experience with CDK4/6 Inhibitors for Metastatic HR+/HER2- Breast Cancer at a Single Cancer Center. The Oncologist. PMID 35666660 DOI: 10.1093/oncolo/oyac089 |
0.081 |
|
| 2011 |
Witkiewicz AK, Knudsen ES. RB pathway and therapeutic sensitivity: new insights in breast cancer and Tamoxifen therapy. Cell Cycle (Georgetown, Tex.). 10: 1525. PMID 21502809 DOI: 10.4161/cc.10.10.15521 |
0.077 |
|
| 2014 |
Witkiewicz AK, Balaji U, Knudsen ES. Systematically defining single-gene determinants of response to neoadjuvant chemotherapy reveals specific biomarkers. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 4837-48. PMID 25047707 DOI: 10.1158/1078-0432.CCR-14-0885 |
0.064 |
|
| 2021 |
Fountzilas C, Bajor DL, Mukherjee S, Saltzman J, Witkiewicz AK, Maguire O, Minderman H, Nambiar R, Rosenheck HR, Knudsen ES, Muhitch JB, Abrams SI, Wang C, Hutson AD, Attwood K, et al. Phase Ib/II study of Cetuximab Plus Pembrolizumab in Patients with Advanced RAS wild-type Colorectal Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 34645646 DOI: 10.1158/1078-0432.CCR-21-1650 |
0.056 |
|
| 2017 |
Knudsen E, Vail P, Balaji U, Ngo H, Botros IW, Makarov V, Riaz N, Balachandran VP, Leach SD, Thompson DM, Chan TA, Witkiewicz AK. Stratification of Pancreatic Ductal Adenocarcinoma: Combinatorial Genetic, Stromal, and Immunological Markers. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28348045 DOI: 10.1158/1078-0432.Ccr-17-0162 |
0.042 |
|
| 2017 |
Knudsen E, Frankel A, Chang J, Witkiewicz A, Haley B. Palbociclib in combination with TDM1 for metastatic HER2+ breast cancer Annals of Oncology. 28: i7. DOI: 10.1093/ANNONC/MDX137.002 |
0.035 |
|
| 2016 |
Schafer IJ, Knudsen E, McNamara LA, Agnihotri S, Rollin PE, Islam A. The Epi Info Viral Hemorrhagic Fever (VHF) Application: A Resource for Outbreak Data Management and Contact Tracing in the 2014-2016 West Africa Ebola Epidemic. The Journal of Infectious Diseases. PMID 27587635 DOI: 10.1093/infdis/jiw272 |
0.033 |
|
| 2009 |
Kulshreshth AK, Alpers A, Herman GT, Knudsen E, Rodek L, Poulsen HF. A GREEDY METHOD FOR RECONSTRUCTING POLYCRYSTALS FROM THREE-DIMENSIONAL X-RAY DIFFRACTION DATA. Inverse Problems and Imaging (Springfield, Mo.). 3: 69. PMID 20126520 DOI: 10.3934/Ipi.2009.3.69 |
0.029 |
|
| 2013 |
Lefmann K, Klenø KH, Birk JO, Hansen BR, Holm SL, Knudsen E, Lieutenant K, von Moos L, Sales M, Willendrup PK, Andersen KH. Simulation of a suite of generic long-pulse neutron instruments to optimize the time structure of the European Spallation Source. The Review of Scientific Instruments. 84: 055106. PMID 23742588 DOI: 10.1063/1.4803167 |
0.024 |
|
| 2004 |
Witt K, Knudsen E, Ditlevsen S, Hollnagel H. Academic detailing has no effect on prescribing of asthma medication in Danish general practice: a 3-year randomized controlled trial with 12-monthly follow-ups. Family Practice. 21: 248-53. PMID 15128684 DOI: 10.1093/Fampra/Cmh306 |
0.022 |
|
| 2014 |
Knudsen ES, Gopal P, Singal AG. The changing landscape of hepatocellular carcinoma: Etiology, genetics, and therapy American Journal of Pathology. 184: 574-583. DOI: 10.1016/j.ajpath.2013.10.028 |
0.021 |
|
| 2015 |
Knudsen E, Franco J, Balaji U, Witkiewicz A. Defining prognostic and therapeutic selective classes of TNBC Annals of Oncology. 26: iii15. DOI: 10.1093/ANNONC/MDV117.09 |
0.017 |
|
| 2004 |
Reventlow SD, Waldorff FB, Witt K, Knudsen E, Kruse T. [Quality assurance of the diagnosis of osteoporosis in a county]. Ugeskrift For Laeger. 166: 2656-9. PMID 15347167 |
0.01 |
|
| Hide low-probability matches. |